Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes-Reference-Cited by-同舟云学术

Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes

Published:2021-02-03 Issue:4 Volume:166 Page:1071-1081
ISSN:0304-8608
Container-title:Archives of Virology
language:en
Short-container-title:Arch Virol

Author:

Abd Alla Mohamed Darwish Ahmed^ORCID,Dawood Reham M.,Rashed Hassan Abd EL-Hafeth,Farrag Galal,Ammar Islam Abdelmawla Emran,Mahmoud Mohamed Mahmoud Abdel-Halim,Salum Ghada M.,Altanbouly Ahmed Mohamed Abdulhamid,El Meguid Mai A.,Awady Mostafa K. El

Publisher

Springer Science and Business Media LLC

Subject

Virology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00705-021-04969-4.pdf

Reference51 articles.

1. Ruane PJ, Ain D, Stryker R, Meshrekey R et al (2015) Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62(5):1040–1046

2. Doss W, Shiha G, Hassany M, Soliman R et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581–585

3. Eletreby R, Elakel W, Said M, El Kassas M et al (2017) Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int 37(4):534–541

4. Eletreby R, Elakel W, El Raziky M, Esmat G (2017) Response to Real life Egyptian experience of efficacy/safety of Simeprevir\Sofosbuvir in HCV genotype IV. Liver Int 37:766–766

5. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W et al (2015) Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64(6):948–956

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the expression of fibrosis-related genes as non-invasive diagnostic biomarkers for cirrhotic HCV-infected patients;Cytokine;2024-10

2. Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR;Journal of Genetic Engineering and Biotechnology;2023-12

3. HCV treatment outcome depends on SNPs of IFNL3-Gene polymorphisms (rs12979860) and cirrhotic changes in liver parenchyma;Heliyon;2023-11

4. Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal;Hepatoma Research;2023

5. Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients;Heliyon;2022-08